Incytes (INCY) Q1 Earnings & Revenues Fall Shy of Estimates
Incytes (INCY) first-quarter 2024 earnings and revenues miss estimates. The company maintains 2024 revenue guidance for its lead drug, Jakafi.…
100,862$
0,15%
Echtzeit-Aktienkurs Incyte Corp.
Bid:
Ask:
Nachrichten zur Incyte Corp. Aktie
The Zacks Analyst Blog Highlights Biogen, Bristol Myers Squibb, Incyte and Vertex Pharmaceuticals
Biogen, Bristol Myers Squibb, Incyte and Vertex Pharmaceuticals are part of the Zacks top Analyst Blog.…
Incyte (INCY) to Report Q1 Earnings: Whats in the Cards?
Incytes (INCY) first-quarter 2024 revenues are likely to have been driven by the U.S. sales and royalties from Novartis on…
CMS and Incyte Announce Collaboration and License Agreement for Povorcitinib in China and Southeast Asia
HONG KONG, China and WILMINGTON, Del., April 01, 2024 (GLOBE NEWSWIRE) -- China Medical System Holdings Limited (“CMS”…
Incyte (INCY) Posts Positive Results on Opzelura From HS Study
Incytes (INCY) Opzelura leads to a significantly greater reduction in abscess and inflammatory nodule (AN) count in HS patients.…